$LAURUSLABS Financial performance and key operating metrics (consolidated) Operating Revenue for Q1FY27 is Rs. 2,026 Crs., 29.1% growth YoY (driven by (1) higher commercial supplies in CDMO and (2) continued strength in Affordable Medicines), Total Income is Rs. 2,035 Crs., 28.83% growth YoY, Gross Profit is Rs. 1,270 Crs., 36.27% growth YoY, EBITDA is Rs. 638 Crs., 67.03% growth YoY, EBITDA Margin is 31.5% improved by 715 basis points YoY (attributed to operating leverage and capacity efficiency improvement as late-stage and commercial projects scaled), PBT Rs. 481 Crs., 114.68% growth YoY, PAT Rs. 362 Crs. 123.94% growth YoY. On QoQ basis Op. Revenue is up by 11.85%, Total Income is also up by 11.63%, Gross Profit is up by 14.29%, EBITDA is up by 24.64%, EBITDA Margin also improved by 323 BPS, PBT is up by 33.2% and PAT is also up by 28.35%. Segments Update : CDMO (Small Molecules): Step-change in scale; commercial share rising; diversified book, Affordable Medicines: Steady growth, mix normalization, filings and market expansion, Laurus Bio / Fermentation & Biocatalysis: Building scale; 12–18 months pivotal Capex guidance has stepped up materially (1,000 → 1,500 → 2,000 cr. for FY27)

#WatchOutFor#EquityResearch#MacroViews#TrendingSectors#FundamentalViews

791 likes·44 comments